Loading stock data…
RPRX
$51.65+0.86 (+1.69%)
Market ClosedLast close May 11
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Royalty Pharma plc in the Healthcare sector is trading at $51.65. The stock is currently near its 52-week high of $51.72, remaining 26.7% above its 200-day moving average. Technical signals show neutral RSI of 70 and bullish MACD crossover, explaining why RPRX maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 70) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$51.65
Potential Downside
24.3%
Whystock Fair Value$39.11
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-sta...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$29.47B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
27.93
Beta
Defensive asset. Lower volatility than the S&P 500.
0.39
Div Yield
Strong income play. Yield provides a meaningful total return floor.
190.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.76%
Volume
Today's trading volume
2.68M
Recent News
Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend Soon
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally
Centerra Gold operates integrated mining projects in North America and Turkey, generating revenue from gold, copper, and molybdenum sales.
This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge
Preformed Line Products designs and manufactures network hardware for utilities and telecoms across global infrastructure markets.
10% Of This Royalty Pharma Insider's Holdings Were Sold
From what we can see, insiders were net sellers in Royalty Pharma plc's ( NASDAQ:RPRX ) during the past 12 months. That...
Royalty Pharma Q1 Earnings Call Highlights
Royalty Pharma (NASDAQ:RPRX) reported what executives described as a “strong start” to 2026, driven by double-digit growth in cash receipts, active capital deployment and a series of clinical and regulatory developments across its portfolio, according to management’s remarks on the company’s first-q